New Insights from EMBRACE Phase 2a Study on Emapalumab in Treating Sepsis Recent results from the EMBRACE Phase 2a study show promising outcomes for emapalumab in treating interferon-gamma-driven sepsis.

New Insights from EMBRACE Phase 2a Study on Emapalumab in Treating Sepsis #Sweden #Stockholm #sepsis #Gamifant #emapalumab

Clinical experience with #emapalumab treatment in a group of children with primary hemophagocytic lymphohistiocytosis. A new study from Yulia Rodina et al.: rupress.org/jhi/article/...

#Therapeutics #Hemophagocytosis

In @jhumimmunity.org, Yulia Rodina et al. explore the use of #emapalumab, an interferon gamma inhibitor, in seven children with primary hemophagocytic lymphohistiocytosis. rupress.org/jhi/article/...

#Therapeutics #hemophagocytosis

Yulia Rodina et al. explore the use of #emapalumab, an interferon gamma inhibitor, in seven children with primary hemophagocytic lymphohistiocytosis. rupress.org/jhi/article/...

#Therapeutics #hemophagocytosis

Sobi Unveils Novel Findings on Rare Inflammatory Disorders at ACR 2025 Sobi presents groundbreaking data on rare inflammatory diseases at ACR 2025, highlighting advancements in treatments for uncontrolled gout and other conditions.

Sobi Unveils Novel Findings on Rare Inflammatory Disorders at ACR 2025 #Sweden #Stockholm #Sobi #ACR #emapalumab

Sobi's New Research Collaboration for Gamifant® in Sepsis Aims to Revolutionize Treatment Options Sobi has unveiled a significant research collaboration to advance Gamifant® (emapalumab) for treating a severe form of sepsis, to be discussed at ISICEM.

Sobi's New Research Collaboration for Gamifant® in Sepsis Aims to Revolutionize Treatment Options #Sweden #Stockholm #Sobi #Gamifant #emapalumab

Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade - Journal of Clinical Immunology

#MedSky #Oncology Blocking PD1 and IFN-gamma helps controlling EBV-driven #hemophagocytosis : Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined #Emapalumab and PD1- Blockade.

link.springer.com/article/10.1...

pubmed.ncbi.nlm.nih.gov/38400989/